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Current therapeutic approaches for Parkinson's disease (PD) are based around treat-
ments that alleviate symptoms but do not slow or prevent disease progression. As
such, alternative strategies are needed. A promising approach is the use of molecules
that reduce the function of leucine-rich repeat kinase (LRRK2). Gain-of-function
mutations in LRRK2 account for a notable proportion of familial Parkinson's disease
cases, and significantly, elevated LRRK2 kinase activity is reported in idiopathic
Parkinson's disease. Here, we describe progress in finding therapeutically effective
LRRK2 inhibitors, summarising studies that range from in vitro experiments to clinical
trials. LRRK2 is a complex protein with two enzymatic activities and a myriad of func-
tions. This creates opportunities for a rich variety of strategies and also increases the
risk of unintended consequences. We comment on the strength and limitations of
the different approaches and conclude that with two molecules under clinical trial
and a diversity of alternative options in the pipeline, there is cause for optimism.
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1 | PARKINSON'S DISEASE (PD)
Parkinson's disease (PD) is a movement disorder that has been
observed in humans since ancient times but was first studied as a dis-
tinct condition by the English physician James Parkinson, who publi-
shed his ‘essay on the shaking palsy’ in 1817 (Parkinson, 1817).
Today, PD is recognised as the second most common neurodegenera-
tive disease, affecting up to 10 million individuals worldwide, with a
lifetime risk estimated around 2% (Elbaz et al., 2002; Gan-Or
et al., 2015). Despite so many years of study and so many affected
individuals, PD is an incurable condition.
PD is predominantly a disease of the elderly, with most sufferers
over the age of 60 (Reeve et al., 2014). The condition is usually con-
sidered both sporadic and idiopathic, with contributions to disease
risk coming from an individual's genetics and their lifetime exposure
to environmental factors, but with age by far the most important fac-
tor (Farrer, 2006; Reeve et al., 2014). Nonetheless, clear patterns of
Mendelian inheritance are apparent in around 10% of patients (Rocca
et al., 2004; Sveinbjörnsdottir et al., 2000). Patients typically present
with a tetrad of motor features, namely, resting tremor, muscle rigid-
ity, posture instability and bradykinesia (Postuma et al., 2015). Of
these, resting tremor is often the first symptom to present and is per-
haps the most distinctive of the condition when compared with other
motor disorders. It is now well established that these oftentimes
debilitating symptoms are due to the degeneration of dopaminergic
neurons within the substantia nigra pars compacta, which leads to a
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depletion of the neurotransmitter dopamine (Postuma et al., 2015).
However, PD is not limited to motor dysfunction (Pfeiffer, 2016). Sev-
eral neuronal networks are affected, causing patients to also suffer
from psychiatric and dysautonomic problems, and as the disease pro-
gresses, cognitive problems can develop (Pfeiffer, 2016). More com-
mon nonmotor symptoms include anosmia, depression and
constipation. Because these nonmotor symptoms can occur more
than 10 years prior to the onset of motor symptoms and diagnosis,
prodomal PD is currently a research area attracting great attention.
From a pharmacological perspective, it is most important to
emphasise that existing PD treatments only alleviate symptoms and
do not delay or halt progression of the disease (AlDakheel
et al., 2014). Current therapeutic approaches for PD are summarised
in Table 1. The majority of these treatments aim to restore motor
function by re-establishing dopamine signalling (AlDakheel
et al., 2014) and are derived from pioneering studies by Arvid Carlsson
who demonstrated that injection of the dopamine biosynthesis pre-
cursor L-dehydroxyphenylalanine (L-DOPA) rescued motor function in
animal models (Carlsson et al., 1957). It took the best part of a decade
to find a suitable dosing and delivery regimen for human PD patients
(Cotzias et al., 1967), but oral L-DOPA and conceptually similar dopa-
mine receptor agonists have been the mainstay of PD treatment ever
since. For any drug, such enduring popularity would usually indicate
that it is a highly efficacious and problem-free compound, and it is cer-
tainly true that after starting L-DOPA PD patients often experience a
honeymoon period lasting several years, where motor symptoms may
be in almost complete abeyance. But symptoms inevitably return as
the disease progresses and the dopamine replacement therapies
themselves can cause some fairly serious side effects, not least
L-DOPA-induced dyskinesias (Tran et al., 2018). Furthermore, these
treatments do not address the majority of nonmotor symptoms, which
typically do not involve loss of dopamine neurones (Chaudhuri
et al., 2006; Postuma et al., 2015). PD patients will require additional
medications to treat these symptoms, such as selective 5-HT
(serotonin) reuptake inhibitors for the treatment of depression
(AlDakheel et al., 2014). But perhaps the most fundamental limitation
of dopamine receptor agonists is that these compounds do not affect
the progression of the underlying neurodegeneration.
The need for new therapeutic strategies for PD is clear. More-
over, because the world's population is ageing, it is also clear that this
need is growing (Reeve et al., 2014). Over recent years, a great deal of
research has therefore been directed towards the genetic causes
of PD, in the hope that these will point the way to novel drug targets.
Therapeutic strategies that target proteins involved in PD aetiology
offer great potential. In principle, such approaches may not only arrest
PD progression but also may even be sufficient to prevent disease in
the first place.
The rest of this article deals with the current state of play
regarding pharmacological inhibitors of leucine-rich repeat kinase 2
(LRRK2), the product of a gene that is strongly implicated as both a
cause of familial PD and an important risk factor contributing towards
the more common sporadic form of the condition (Kluss et al., 2019;
Nalls et al., 2014; Paisan-Ruiz et al., 2004; Zimprich et al., 2004). For
reasons we outline below, targeting LRRK2 may be fruitful not only
for individuals with pathogenic LRRK2 mutations but potentially also
for the majority of PD patients whose LRRK2 status is likely to be nor-
mal. Nonetheless, LRRK2 inhibitors are far more likely to form part of
a next generation of PD treatments, alongside therapies targeting
TABLE 1 Overview of the current treatments for Parkinson's disease
Target Strategy Treatment
Motor symptoms (loss of dopaminergic
neurons and striatal dopamine
depletion)
Dopamine replacement Dopamine precursor (e.g. L-DOPA),
dopamine agonists (e.g. ropinirole)
Inhibition of dopamine degradation MAO-B inhibitors (e.g. rasagiline) and
catecholamine-O-methyltransferase
inhibitors (e.g. entacapone)
Glutamatergic activity decrease (promote
dopamine synthesis) and other
neurotransmitters
Amantadine, NMDA receptor antagonist
and cholinesterase inhibitors
Surgical intervention For example, deep brain stimulation
Nonpharmacological approaches Exercise, rehabilitative therapy and
physiotherapy
Nonmotor symptoms Approaches used in the general population Psychiatric symptoms (e.g. depression,
anxiety and psychosis): dopamine-related
(quetiapine), antidepressants, 5-HT
(serotonin) and noradrenaline reuptake
inhibitors, and cholinesterase inhibitors
Cognitive impairments: cholinesterase
inhibitors and MAO-B inhibitors
Note: This table summarises the most commonly used PD treatments that target motor dysfunction by re-establishing the physiological dopamine
pathway. However, some nonmotor symptoms also respond to the treatments (AlDakheel et al., 2014; Armstrong & Okun, 2020; Chaudhuri &
Schapira, 2009; Duty & Jenner, 2011; Jankovic, 2008; Pfeiffer, 2016; Postuma et al., 2015).
Abbreviations: L-DOPA, L-dehydroxyphenylalanine; PD, Parkinson's disease.
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other genes involved in PD aetiology. For example, clinical trials are
currently underway aiming to restore the function of the lysosomal
enzyme glucosylceramidase beta (product of the GBA gene). Strate-
gies employed include gene therapy (NCT04127578; clinicaltrials.gov)
and compounds such as ambroxol (NCT02941822, NCT04388969
and NCT02914366; clinicaltrials.gov) that are expected to act as
molecular chaperones to improve the delivery of glucosylceramidase
beta to the lysosome (Maegawa et al., 2009; Migdalska-Richards
et al., 2017). Direct targeting of α-synuclein is also being pursued. For
example, the aggregation inhibitor anle138b (Wagner et al., 2013) is in
clinical trials (NCT04685265; clinicaltrials.gov), as is the c-Abl inhibitor
nilotinib (NCT02281474; http://clinicaltrials.gov), which is expected
to remove α-synuclein by promoting autophagy (Karuppagounder
et al., 2014). It is hoped that these compounds—in particular when
allied with methods to identify at-risk individuals, such as genetic
screens and research into prodromal PD, to allow earlier
intervention—will become the next generation of PD treatments that
are so desperately needed.
2 | LEUCINE-RICH REPEAT KINASE 2
Leucine-rich repeat kinase 2 protein (LRRK2) is the product of the
LRRK2 gene. LRRK2 was originally discovered independently by two
groups as the gene located within the so-called PARK8 locus—a region
on chromosome 12 associated with autosomal dominant late-onset
parkinsonism (Paisan-Ruiz et al., 2004; Zimprich et al., 2004). Muta-
tions in LRRK2 are now accepted as one of the most common causes
of familial PD (Kluss et al., 2019; Nalls et al., 2014). Pathogenic LRRK2
mutations give rise to phenotypes that, at the individual level, are clin-
ically indistinguishable from those of sporadic PD, including age of
onset, symptoms and patterns of neurodegeneration in nigrostriatal
dopaminergic neurons. Post-mortem LRRK2 brains also display accu-
mulation of Lewy bodies—proteinaceous aggregates typically enriched
in α-synuclein and ubiquitin—that are a pathological hallmark of PD
(Kalia et al., 2015). Curiously, LRRK2 brains also frequently display Tau
protein pathology; although the gene encoding Tau, MAPT has been
strongly implicated in sporadic PD via genome-wide association stud-
ies, the accumulation of Tau is usually associated with other neurode-
generative conditions including Alzheimer's disease (Iqbal et al., 2010;
Nalls et al., 2014). Thus, LRRK2 may sit at the top of neurodegenera-
tive cascades involving both α-synuclein and Tau. Complicating mat-
ters further, TAR DNA-binding protein 43 kDa (TDP-43) pathology,
more usually associated with amyotrophic lateral sclerosis, has been
reported in a small number of LRRK2 brains (Ling et al., 2013; Wider
et al., 2010), as have post-mortem brains with no apparent
proteinopathies (Gaig et al., 2007; Takanashi et al., 2018).
Importantly, genome-wide association studies (GWAS) have also
shown that LRRK2 has a major influence on an individual's risk of
developing sporadic PD (Do et al., 2011; Lill et al., 2012; Satake
et al., 2009; Simon-Sanchez et al., 2009). Thus, with gene variants of
different severity either causing familial PD or contributing risk
of sporadic PD, LRRK2 is considered a pleiomorphic risk locus for this
condition (Cookson, 2015) and it is clear that the study of LRRK2 may
have wider implications for other forms of neurodegenerative disease.
Adding an extra layer of complexity, genome-wide association
studies have also implicated LRRK2 as a factor in the genetic risk of
Crohn's disease (Barrett et al., 2008; Franke et al., 2010) and leprosy
(Wang et al., 2015; Zhang et al., 2009), whereas other studies have
linked LRRK2 to tuberculosis (Hartlova et al., 2018). LRRK2 has also
been associated with the risk of cancer but with conflicting results.
Some studies find that the pathogenic LRRK2 variant G2019S
increases the risk of cancer (Agalliu et al., 2015; Inzelberg et al., 2012;
Saunders-Pullman et al., 2010), but others do not (Allegra et al., 2014;
Ruiz-Martinez et al., 2014). Interestingly, loss of LRRK2 appears to
increase risk of lung cancer (Lebovitz et al., 2021), an observation that
may be germane to the long-term use of LRRK2 inhibitors (see later in
this article). In any case, the observations linking LRRK2 to Crohn's
disease, tuberculosis and leprosy are curious, because these condi-
tions share some clear similarities with each other (e.g. they are all
chronic inflammatory conditions with other genetic loci in common),
but similarities with PD are less obvious. Whether LRRK2 dysfunction
has a common role in all four conditions or whether the molecular
mechanism in PD is distinct remains to be seen, but it is interesting to
note that although that no shared pathogenic variants have been
identified, the protective R1398H variant appears to be common to
risk of Crohn's disease and PD (Hui et al., 2018; Ross et al., 2011; Tan
et al., 2010). As such, it is easy to imagine that, at the very least,
research into LRRK2 in PD could also have important implications for
these non-neurodegenerative conditions.
LRRK2 itself is a large (2527 amino acid) and very unusual protein
that belongs to the ROCO family of GTPases and contains multiple
functional domains (Gotthardt et al., 2008; Paisan-Ruiz et al., 2004;
Zimprich et al., 2004). The structure of LRRK2 is depicted in Figure 1.
In addition to the four protein–protein interaction domains, LRRK2
contains domains conferring both serine–threonine kinase activity
and GTPase activity, the latter via the combination of a Ras of com-
plex proteins (Roc) domain and a C-terminal of Roc (COR) domain,
which are often collectively referred to as a Roc–COR tandem domain
(Gotthardt et al., 2008). A number of pathogenic mutations have been
found, all of which encode single amino acid substitutions with the
Roc, COR and kinase domains, although a relatively common variant
associated with increased risk encodes a G2385R amino acid substitu-
tion with the WD40 domain, at the C-terminus of the protein
(Berwick et al., 2019; Kluss et al., 2019). Typically, LRRK2 exists in
cells as both homodimers and monomers, with dimerisation suggested
to regulate LRRK2 subcellular location and function (Ho et al., 2018).
Fascinatingly, monomers are generally cytosolic, whereas dimers are
predominantly located on organelle membranes (Berwick &
Harvey, 2012; Nichols et al., 2010), and membrane-bound LRRK2 has
been reported to possess a higher kinase activity (Berger et al., 2010).
Thus, LRRK2 dimerisation and membrane recruitment have been
suggested to play a role in kinase activation, perhaps in a mechanism
governed by the membrane-bound small GTPase Rab29, which has
been shown to bind LRRK2 and increase its kinase activity in cells (Liu
et al., 2018; Purlyte et al., 2019).
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The biological function of LRRK2 within cells remains unclear,
largely because this protein has been linked to a multitude of different
cell biological processes and a clear front runner has yet to emerge
from the pack. For example, LRRK2 has been linked to effects on cell
signalling, microtubule and other cytoskeletal dynamics, ciliogenesis,
autophagy, endocytosis, synaptic vesicle trafficking and the biology of
numerous cellular organelles such as mitochondria, the trans-Golgi
network and lysosomes (reviewed by Berwick et al., 2019). Complicat-
ing things further, there is no real agreement over the type of cells in
which LRRK2 dysfunction is most important for PD, with published
data supporting many neural cell types and also immune cells
(Berwick et al., 2019). In principle, therefore, LRRK2 dysfunction could
cause either degeneration of dopaminergic neurons via a cell autono-
mous process or via a noncell autonomous neuroinflammatory
mechanism—or potentially via both.
Nonetheless, within the context of this review, the uncertainty
regarding LRRK2 function is not of great importance. This is because
when it comes to the effects of LRRK2 pathogenic mutations on
LRRK2 itself, there is clear consensus on two key points:
1. All pathogenic LRRK2 mutations increase both LRRK2
autophosphorylation and the LRRK2-mediated phosphorylation of
certain Rab small GTPases in cells. Whether all these mutations
technically increase LRRK2 kinase activity is debatable, because
only the common G2019S kinase domain mutation reproducibly
increases kinase activity in biochemical assays performed in vitro
(Greggio & Cookson, 2009). Furthermore, the G2385R risk variant
is actually reported to reduce kinase activity in these experiments
(Rudenko et al., 2012). However, this argument is ultimately a
semantic one—the effect of all PD-causing or PD risk mutations in
LRRK2 is to increase substrate phosphorylation in vivo (Berwick
et al., 2019; Kluss et al., 2019). To most intents and purposes,
therefore, they can be considered to increase kinase activity; at
the very least, they are gains of kinase function.
2. All pathogenic LRRK2 mutations within the Roc or COR domains
increase the fraction of GTP-bound LRRK2 relative to GDP-bound
LRRK2. This phenomenon is achieved either via increased binding
of the LRRK2 Roc domain to GTP, or via a decrease in the catalytic
activity of this domain (i.e. there is less hydrolysis of GTP to GDP),
or via a combination of both mechanisms (Nixon-Abell, Berwick, &
Harvey, 2016). Supporting the idea that GTP-bound LRRK2 is a
more pathogenic species, the protective LRRK2 risk variant,
R1398H, displays decreased GTP-binding and increased GTPase
activity and can therefore be expected to exist in a more GDP-
bound state (Nixon-Abell, Berwick, Granno, et al., 2016).
Thus, there are clear and largely unambiguous correlations
between increased LRRK2 kinase function in vivo and PD and
between the increased association of LRRK2 with GTP and PD. How
these mechanisms relate to each other is not yet fully understood,
with biochemical evidence indicating that the two enzymatic activities
of LRRK2 are to some extent interdependent. However, the fact that
all pathogenic mutations promote substrate phosphorylation under
physiological conditions indicates that increased kinase function is the
pathogenic ‘output’ of LRRK2, even if the increased kinase function is
not always increased kinase activity per se. Underscoring this idea,
increased LRRK2 autophosphorylation and increased phosphorylation
of the LRRK2 substrate Rab10 have also been observed in PD and
animal models of PD that do not involve pathogenic LRRK2 mutations
(Di Maio et al., 2018). Importantly, these include post-mortem brains
from human patients with sporadic PD, as well as brains from rats that
overexpress α-synuclein or have been treated with the environmental
toxin rotenone (Di Maio et al., 2018). As such, it can be assumed that
multiple causes of PD—genetic and environmental—can give rise to
increased LRRK2 kinase function and thus PD.
Although it has taken some time for the experimental evidence to
convincingly support this idea, largely due the time taken for
researchers to identify Rab proteins as the first widely agreed bona
F IGURE 1 Leucine rich repeat kinase 2 (LRRK2) structure and mutations. LRRK2 is a homodimer belonging to the ROCO family of GTPases.
LRRK2 contains multiple domains: protein–protein interaction domains ARM (armadillo), ANK (ankyrin-like), LRR (leucine-rich repeat) and WD40
(all in pink); a serine–threonine kinase domain (in orange); and a Roc (Ras of complex proteins)–COR (C-terminal of Roc) tandem domain
conferring GTPase activity (in blue). The arrows indicate the putative intramolecular interactions. The locations of the pathogenic mutations are
indicated in red; the risk variants are indicated in purple; and the protective variant is indicated in green
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fide LRRK2 substrates, autosomal dominant mutations in a kinase
gene can logically be expected to increase the enzymatic activity of
that kinase. Thus, from the perspective of the pharmaceutical indus-
try, the identification of LRRK2 as an autosomal dominant cause of
hereditary PD was sufficient rationale to begin developing compounds
that reduce LRRK2 kinase activity, irrespective of how well the
assumed increased kinase function had actually been demonstrated
empirically. As a result, the quest to develop LRRK2 inhibitors as can-
didate therapeutic treatments for PD began very early, with multiple
companies involved, as well as considerable backing from the charita-
ble sector. In fact, the pursuit of a clinically usable LRRK2 inhibitor has
progressed to such an extent that clinical trials of one such compound
in sporadic PD patients were announced only a matter of weeks after
the first evidence that LRRK2 kinase function is actually increased in
this cohort (Denali Therapeutics, 2018; Di Maio et al., 2018). In short,
the progress of LRRK2 drug development relative to basic research
into this protein is quite remarkable.
In the subsequent three sections of this article, we summarise the
development of conventional LRRK2 kinase inhibitors, while also
identifying potential risks and challenges in the road ahead. For more
detailed descriptions of the chemistry of these molecules, we point
the reader to the following more specialised reviews (Domingos
et al., 2019; Hatcher et al., 2017). Later in the manuscript, we branch
out to alternative pharmacological strategies to reduce the function of
this protein, which together create a rich palette of potential
therapeutic options.
3 | ATP-COMPETITIVE LRRK2 KINASE
INHIBITORS
The majority of molecules targeting LRRK2 have been conventional
or ‘Type I’ kinase inhibitors, which compete with ATP for binding to
the ATP-binding pocket within the kinase domain (Hatcher
et al., 2017; Lu et al., 2020). This story inevitably began with com-
pounds that were a long way from candidate drugs ready to enter
clinical trials, but over the years, these molecules have evolved to
have superior pharmacological profiles and one compound is now in
clinical trials.
The first compounds reported to inhibit LRRK2 kinase activity
were either broad-range kinase inhibitors able to inhibit LRRK2 with
high potency but very low selectivity, for example, staurosporine,
which has IC50 values for LRRK2 of 1–2 nM (Anand et al., 2009; Covy
& Giasson, 2009), or a series of Rho kinase inhibitors that were found
to inhibit LRRK2 and Rho kinases with similar high nanomolar poten-
cies (Nichols et al., 2009). Fortunately, these compounds were swiftly
superseded by two more selective molecules, LRRK2-IN-1 (Deng
et al., 2011) and CZC-25146 (Ramsden et al., 2011), which were iden-
tified specifically as LRRK2 inhibitors via kinase inhibitor library
screens. Both these compounds are reported to inhibit LRRK2 with
IC50s in the low nanomolar range and exhibit decent selectivity; for
example, LRRK2-IN-1 was found to display greater than 90% inhibi-
tion towards only 12 out of 440 kinases using an Ambit KINOMEscan
that measures the binding of drugs to a panel of kinases as a proxy for
kinase inhibition (Deng et al., 2011; Karaman et al., 2008).
The chemical structures of LRRK2-IN-1 and CZC-25146 and
other selective LRRK2 inhibitors that are specifically mentioned within
this article are shown in Figure 2.
In addition to LRRK2-IN-1 and CZC-25146, the first generation of
LRRK2 inhibitors also included another high MW diaminopyrimidine
named TAE684, a repurposed anaplastic lymphoma kinase (ALK)
inhibitor with a similar potency but a slightly inferior selectivity
(Zhang et al., 2012). Aminopyrimidines were not the only structural
category represented however, with GSK2578215A, a potent
(IC50 = 9 nM) and selective (90% inhibition towards only three out
of 449 kinases) arylbenzamide, also being reported in 2012
(Reith et al., 2012). These four compounds have been integral to a great
deal of basic research carried out over subsequent years, aided in part
by the Michael J. Fox Foundation making them easily available to
scientists worldwide. Nonetheless, as drugs for the clinic, all four
compounds perished early in the pipeline. LRRK2-IN-1 and CZC-25146
had the critical failing of being unable to cross the blood–brain barrier,
which is clearly a fundamental requirement of any pharmaceutical
aimed at treating neurodegenerative disease. Somewhat surprisingly,
the structurally similar but larger compound TAE684 did enter the brain
in rodents, but it was found to be ineffective as a LRRK2 inhibitor in
this organ. GSK2578215A, which is appreciably smaller than all three
aminopyrimidine molecules, also crossed the rodent blood–brain barrier
with little effect on LRRK2.
Given that LRRK2-IN-1, CZC-25146 and TAE684 are all similar in
structure, it is unsurprising that a great many of the next generation
of LRRK2 kinase inhibitors were smaller aminopyrimidine molecules
that were developed with the hope of retaining potency and selectiv-
ity for LRRK2, while facilitating access to the brain. A number of such
compounds were published in the next few years including HG-
10-102-01 (Chen et al., 2012; Choi et al., 2012) and a series of
compounds—G1023, GNE-7915, GNE-0877 and GNE-9605—made
by Genentech (Estrada et al., 2012, 2014). All these compounds have
potencies in the low (or sub-molar) nanomolar range and excellent
selectivity and are able to enter the brains of mice and inhibit LRRK2
in vivo. The Genentech compounds were also tested in rats and
cynomolgus monkeys, where they were found to have good pharma-
cokinetic and drug metabolism profiles (Estrada et al., 2012, 2014).
Thus, LRRK2 kinase inhibitors moved from purely in vitro tools to
compounds that could be used to study LRRK2 in the brains of animal
models.
Over the next few years, a number of other structurally
distinct LRRK2 kinase inhibitors (i.e. neither aminopyridines nor
arylbenzamides) have been reported in the scientific literature, as
these compounds continue to evolve and improve. Structural catego-
ries include pyrrolopyrimidines such as Pfizer's PF-06447475
(Henderson et al., 2015), indazoles such as Merck's MLi-2 (Fell
et al., 2015) and thiophenes, also from Merck (Greshock et al., 2016).
In addition, further types of organic molecules that have not been
described in the scientific literature are the subject of patents for use
as LRRK2 inhibitors, such as macrocyclic derivatives from
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GlaxoSmithKline and Ipsen Pharma (Ding & Ren, 2020). For a detailed
review of the chemistry, we refer the reader to existing work in this
area (Domingos et al., 2019; Hatcher et al., 2017).
One recent development that is worthy of mention, however, is
the discovery of ATP-competitive LRRK2 inhibitors that exhibit selec-
tivity for the pathogenic G2019S LRRK2 variant over wild-type
LRRK2 (Garofalo et al., 2020). Via compound library screening
followed by in silico docking analysis and systematic chemical modifi-
cations, Garofalo et al. (2020) identified a number of indazole mole-
cules displaying selectivity for G2019S. The most selective compound
was reported to have a >300 greater potency in cellular assays and
>200 greater potency in vitro. As the authors themselves rightly
observe, this ‘is remarkable, given that G2019S-LRRK2 differs from
WT-LRRK2 only by a single amino acid’ (Garofalo et al., 2020).
Unfortunately, this molecule is unlikely to be developed further as it is
unable to cross the blood–brain barrier, but we note that another
G2019S-selective indazole compound identified in the same work has
since been shown to inhibit LRRK2 kinase activity in peripheral blood
mononuclear cells from homozygous G2019S LRRK2 patients, but not
in cells from wild-type controls (Bright et al., 2021). Thus, even though
these molecules may only be suitable for G2019S LRRK2 PD patients,
there is clearly a lot of potential in this project and we await further
developments.
Taking this section as a whole, it is evident that there are a multi-
tude of promising ATP-competitive LRRK2 kinase inhibitors in the
pipeline. As therapeutics for the treatment of PD, most of these com-
pounds will inevitably fall by the wayside, but with a diversity of
chemical structures available, there are good grounds for optimism. A
F IGURE 2 Chemical structures of the
leucine rich repeat kinase 2 (LRRK2)
inhibitors described in this review. The
chemical structures of the selective
LRRK2 inhibitors mentioned by name in
this article are shown. Structures were
generated using ACD/ChemSketch (ACD
Labs) with structures cleaned and most
likely tautomeric forms selected
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variety of chemical structures means a greater range of pharmacologi-
cal properties and a better chance of finding a drug that is potent,
selective and free from adverse effects. Later in this article, we will
focus on LRRK2 inhibitors that are or have been used in human clini-
cal trials, but before we get to that point, we will first comment on
certain areas of concern that have been raised in preclinical studies.
4 | AREAS OF CONCERN FOR THE LRRK2
KINASE INHIBITOR DRUG PIPELINE
As mentioned, LRRK2 kinase inhibitors have been in development
for well over a decade as a potential therapeutic strategy
for PD. Nonetheless, there have long been concerns about this strat-
egy that go beyond the now resolved difficulty in demonstrating ele-
vated LRRK2 kinase function for any variant other than G2019S. For
example, LRRK2 kinase inhibitors have been shown to display similar
effects to pathogenic mutants in some cellular assays, for example,
their effects on canonical Wnt signalling (Berwick et al., 2017;
Berwick & Harvey, 2012) and binding of LRRK2 to filamentous
microtubule structures (Blanca Ramirez et al., 2017; Schmidt
et al., 2019). Thus, there is a potential that LRRK2 inhibition may
increase certain PD symptoms. In addition, there is evidence that
prolonged inhibition can lead to loss of protein stability, thereby
compromising all functions of LRRK2, not just those that are kinase
dependent (West, 2017). Although this can in principle be addressed
by keeping the therapeutic dose within a tight window, this is
potentially a serious problem, as LRRK2 has hundreds of reported
interacting partners and is believed also to act as a scaffolding protein,
not just as a kinase (Berwick et al., 2019; Lewis & Manzoni, 2012).
The greatest worry perhaps inevitably comes from in vivo studies
of Lrrk2 knockout mice and rats. Mice that are double knockout for
both Lrrk2 and its paralog Lrrk1 display neurodegeneration (Giaime
et al., 2017), yet because animals that only lack Lrrk2 have no overt
neurological phenotypes (for a detailed review of LRRK2 animal
models, see Seegobin et al., 2020), this concern does not relate to the
brain. Instead, Lrrk2 knockout mice and rats display an unusual vacuo-
lated phenotype in their kidneys, liver and lung (Baptista et al., 2013;
Ness et al., 2013; Seegobin et al., 2020; Tong et al., 2010). None of
these alterations appear to have any significant impacts on the health
of these laboratory animals, but the lung phenotype is a particular
concern given that respiratory problems are very common in PD (van
de Wetering-van Dongen et al., 2020), so any further compromise to
lung function could ultimately lead to a worsened clinical outcome.
This concern was intensified following an investigation into the effect
of two of the Genentech aminopyridine inhibitors, GNE-7915 and
GNE-0877, in cynomolgus monkeys (Fuji et al., 2015). Worryingly,
treatment of these animals with either compound caused vacuolated
Type II pneumocytes, which was very consistent in appearance with
the lung phenotype of Lrrk2 knockout mice and rats. Subsequently, a
similar effect was observed in mice treated with the indazole LRRK2
inhibitor MLi-2 developed by Merck (Fell et al., 2015). However, a
recent dedicated toxicological study using GNE-7915, MLi-2 and the
Pfizer LRRK2 inhibitor PFE-360 in cynomolgus has indicated that
these fears may be exaggerated (Baptista et al., 2020). Although each
compound induced the same vacuolated Type II pneumocyte
phenotype, thereby confirming that this is an on-target effect of
LRRK2 kinase inhibition, lung function studies on the GNE-7915 and
MLi-2-treated animals did not reveal any apparent limitations
(the PFE-360-treated cohort was not examined). Importantly, other
experiments indicate that the phenotype is reversible following with-
drawal from treatment and that the PFE-360 compound, in particular,
might be able to operate at a no-effect dose, where brain LRRK2
kinase activity is inhibited, but the lung phenotype is not observed
(Baptista et al., 2020). As such, the worst case scenario seems to be
that the lung phenotype can be avoided with adequate dosing and, if
it does occur, the phenotype can be treated and is unlikely to have
much of an impact anyway. Supporting this further are recent studies
of humans carrying heterozygous loss-of-function LRRK2 variants. It
had already been reported that individuals with low expression of
LRRK2 have no increased risk of PD (Blauwendraat et al., 2018), but
the work of Whiffin et al. (2020) has extended this to a wide range of
clinical outcomes. Using health records of individuals heterozygous
for LRRK2 variants containing premature stop codons, this group
reported no increased frequency of ‘lung, liver, kidney, cardiovascular
system, nervous system, immunity or cancer’ phenotypes (Whiffin
et al., 2020). However, these results are to some extent contradicted
by a more recent report associating LRRK2 loss-of-function with a
type of lung cancer that appears to be Type II pneumocyte in origin
(Lebovitz et al., 2021). This group had previously reported lowered
LRRK2 expression in lung adenocarcinoma (Lebovitz et al., 2015) but
have since looked at the connection in greater detail. They report that
lower levels of LRRK2 are associated with decreased patient survival
and that Lrrk2 KO mice are more prone to developing lung adenomas
when exposed to urethane, a cigarette smoke carcinogen (Lebovitz
et al., 2021). These results are concerning, but it is probably pertinent
to observe that lower LRRK2 expression is most strongly correlated
with lung cancer in patients who are smokers and that there is
currently little evidence to suggest decreased LRRK2 expression is
sufficient to cause lung cancer (Lebovitz et al., 2021). Thus, LRRK2
inhibitors may not be suitable for current or recent smokers,
but otherwise, the risk of lung cancer appears small.
A further complication is how to reliably measure the extent of
LRRK2 kinase inhibition within the brains of patients, such that clini-
cians can establish an optimal dose and monitor treatment progres-
sion in their patients. Existing biomarkers, such as Rab protein
phosphorylation (Eyers, 2018; Steger et al., 2016) or LRRK2
autophosphorylation on serine-1,292 (Sheng et al., 2012), which can
be measured with phospho-specific antibodies, appear to be faithful
proxies for LRRK2 kinase function in brain tissue from experimental
animals, but these assays cannot easily be replicated on humans. Less
invasive procedures will be needed, for example, proteins or metabo-
lites present in patient blood or urine samples, although correlating
these readouts with LRRK2 kinase inhibition in brain tissue is going to
be a tough ask. With this in mind, we note that certain
bis(monoacylglycerol)phosphates (BMP), phospholipids that are
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considered specific to lysosomes, have been reported to be increased
in the urine of LRRK2 PD patients (Alcalay et al., 2020) and also
decreased in the urine of both cynomolgus monkeys treated with
LRRK2 kinase inhibitors and Lrrk2 knockout mice (Fuji et al., 2015). As
such, urine BMP levels may be an ideal non-invasive biomarker. It
should be noted that sporadic PD patients do not appear to have ele-
vated urine BMP levels compared with healthy controls (Alcalay
et al., 2020). However, the same study found that in PD patients urine
BMP levels appear to be inversely correlated with cognitive perfor-
mance irrespective of LRRK2 status. Thus, the overall difference in
urine BMP levels between sporadic PD and control cohorts is likely a
consequence of heterogeneity within each group and that at an indi-
vidual level at least, urine BMP levels may be a faithful biomarker of
disease progression (Alcalay et al., 2020). The full potential of BMP
remains to be established, but unsurprisingly, this biomarker is already
being used in clinical trials of LRRK2 inhibitors (Denali
Therapeutics, 2020).
5 | LRRK2 KINASE INHIBITORS IN
CLINICAL TRIALS
Although the field is very crowded, to date just two LRRK2 kinase
inhibitors have been used in clinical trials: compounds DNL-201 and
DNL-151, which are manufactured by Denali Therapeutics. Neither of
these compounds have been described in the scientific literature,
although it has been observed that this company published four pat-
ents that cover the use of an array of aminopyrimidine compounds in
2017 and 2018 (Ding & Ren, 2020), around the time trials began.
In Phase 1a trials, both compounds were well tolerated in healthy vol-
unteers at doses that ‘achieved high levels of CSF exposure, robust
target engagement as measured by two blood-based biomarkers of
LRRK2 activity, and effects on biomarkers of lysosomal function’
(Denali Therapeutics, 2018). It can be assumed that the blood
biomarkers of LRRK2 activity were measurements of LRRK2
autophosphorylation or Rab protein phosphorylation or, alternatively,
phosphorylation of LRRK2 at one or more of a series of serine resi-
dues within the LRR domain that are dependent on, but not directly
mediated by, LRRK2 kinase activity (Kelly & West, 2020). Indeed,
phosphorylation of Rab10 and LRRK2 phosphorylation on the serine-
935 LRR domain site in peripheral blood mononuclear cells and whole
blood are mentioned as secondary outcome measures within the
Phase 1b clinical trial listings for the DNL-201 and DNL-151
(NCT03710707 and NCT04056689, respectively; clinicaltrials.gov).
The assay of lysosomal function is not described in the clinical trial
listings but is likely to be urine BMP levels, as mentioned in a subse-
quent announcement (Denali Therapeutics, 2020).
The trial has been expanded to PD patients in Phase 1b trials,
with both compounds reporting good results. In light of the lung phe-
notype and the particular risk of respiratory impairment in PD, this is
good news. Nonetheless, Denali have announced their intention to
focus only on DNL-151 as Phase 1b trials are extended to cover a
wider range of doses, as this compound has ‘pharmacokinetic
properties that provide additional dosing regimen flexibility’ (Denali
Therapeutics, 2020).
So what is the situation with other LRRK2 kinase inhibitors? At
present, with Denali over 2 years into testing, it can be assumed that
other companies are waiting for the full results of DNL-151's Phase
1 and 2 trials, before deciding whether to press ahead with their own
compounds. Watching keenly will be Cerevel, who have a LRRK2
inhibitor listed as one of their pipeline drugs on their website
(Cerevel, 2021) and have acquired the rights to Pfizer's neurological
disease compounds. Presumably, this includes the pyrrolopyrimidine
compound PFE-360, which, as mentioned above, was found to have a
no-effect dose at which it inhibited LRRK2 in monkey brains but did
not induce any lung phenotype (Baptista et al., 2020). Also paying
close attention will be Merck, whose MLi-2 compound also showed
signs of a no-effect dose, albeit within a much narrower window than
was observed for PFE-360 (Baptista et al., 2020). Perhaps importantly,
this drug has an especially high potency, with an IC50 in the high pic-
omolar range (Fell et al., 2015). Clearly, Cerevel and Merck will not be
the only interested parties. Thus, although the world plays wait and
see, we can at least do so safe in the knowledge that if DNL-151 fails,
there are plenty of alternative options.
6 | OTHER THERAPEUTIC APPROACHES
TO REDUCE LRRK2 FUNCTION
Although there are plenty of alternative LRRK2 kinase inhibitors to
DNL-151, there are also plenty of therapeutic strategies for reducing
the function of LRRK2 that do not involve classical ATP-competitive
kinase inhibition (Figure 3). This smorgasbord of approaches broadens
the targets of potential therapeutic drugs far beyond the kinase
domain and includes molecules that affect LRRK2 conformation,
protein–protein interactions, GTPase activity and even LRRK2 mRNA.
We describe these molecules in the following sections.
7 | LRRK2 GTP-BINDING INHIBITORS
In addition to the LRRK2 kinase domain, the second enzymatic
activity of LRRK2 represents another interesting drug target. Because
there are only four ROCO GTPases in humans—LRRK1, LRRK2,
death-associated protein kinase (DAPK) 1 and malignant fibrous
histiocytoma-amplified sequence with leucine-rich tandem repeats
1 (MASL1) (Tomkins et al., 2018)—molecules targeting LRRK2 GTP
binding have the potential to be especially selective. Moreover, there
is also sound rationale for such compounds, as decreasing the propor-
tion of pathogenic LRRK2 existing in a GTP-bound state can be
expected to reduce LRRK2 kinase activity and would likely be neuro-
protective. Therefore, selective and blood–brain barrier-permeable
molecules that block LRRK2 GTP binding represent an alternative
option to explore beyond kinase inhibition.
Surprisingly though, research on LRRK2 GTPase inhibitors has
not been prolific and very few research groups in industry or
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academia have actively taken this route. To date, only Wanli Smith's
group has reported LRRK2 GTP-binding inhibitors, the first of which,
compounds 68 and 70, were identified via a computer-aided drug dis-
covery screen (Li et al., 2014). In addition to blocking LRRK2 GTP
binding in cells, these compounds were also able to reduce LRRK2
autophosphorylation, thereby confirming the secondary effect of
inhibiting LRRK2 kinase activity (Li et al., 2014). Demonstrating their
potential, both compounds promoted the survival of cultured neurons,
whereas compound 68 also reduced LPS-induced neuroinflammation
in a mouse model (Li et al., 2014). In subsequent work, this group
reported an optimised analogue of compound 68, FX2149, which is
more brain penetrant and correspondingly more potent in the same
mouse model (Li et al., 2015). To the best of our knowledge, only one
other group has published with these compounds. Fascinatingly,
Blanca Ramirez et al. (2017) reported that compounds 68 and
70 reverse the increased binding of the pathogenic R1441C LRRK2
variant to filamentous microtubule structures. This is in contrast to
LRRK2 kinase inhibitors, which, as mentioned above, were found
to behave like PD-causing mutations in these assays (Blanca Ramirez
et al., 2017). Although these compounds are under patent, we are
unaware of any moves towards entering LRRK2 GTP-binding inhibi-
tors in clinical trials. Nonetheless, the published data indicate that
they have potential.
8 | LRRK2 KNOCKDOWN
Although DNL-151 is the only chemical inhibitor of LRRK2 currently in
clinical trials, it is not the only molecule seeking to reduce LRRK2 func-
tion being examined in humans. As part of a collaboration between
Biogen and Ionis Pharmaceuticals, intrathecal injection of a molecule
called BIIB094 is currently being studied in a Phase 1 clinical trial
(NCT03976349; http://clinicaltrials.gov). As Biogen state on their
website, BIIB094 is an antisense oligonucleotide (ASO) (Biogen, 2021).
Antisense oligonucleotides are single-stranded DNAmolecules of vary-
ing lengths that are designed to bind specifically to an mRNA molecule
of interest via base pair complementarity, typically causing protein syn-
thesis from that mRNA to be blocked (Chery, 2016). The nucleotides
within antisense oligonucleotides are typically chemically modified to
prevent degradation by nucleases, while also facilitating uptake across
F IGURE 3 Sites of action of the leucine rich repeat kinase 2 (LRRK2) inhibitors described in this review. The various types of therapeutic
strategy that are under development or have been proposed for targeting LRRK2 are summarised in the figure. Proposed strategies are written in
italics. For simplicity, non-selective kinase inhibitors (e.g. staurosporine and ponatinib) are omitted. ATP-competitive kinase inhibitors are listed by
chemical class; note that the categorisation of DNL-151 and DNL-201 is presumed on the basis of patents held by the manufacturer
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the plasma membrane and enhancing binding to RNA (Silva
et al., 2020). Importantly, because the mode of delivery used by Biogen
and Ionis is intrathecal injection, that is, directly into the CSF, this strat-
egy obviates the need for BIIB094 to cross the blood–brain barrier. The
use of antisense oligonucleotides to target LRRK2 still carries many of
the same concerns as use of LRRK2 kinase inhibitors and intrathecal
delivery is a fairly invasive means of drug delivery, so there are evi-
dently downsides to this approach. Nonetheless, it is important to note
that the blood–brain barrier works in both directions, so intrathecal
delivery will greatly reduce the chance of adverse effects in the periph-
ery, not least the now familiar lung phenotype.
Fascinatingly, antisense oligonucleotides are already being used
in the clinic for the treatment of spinal muscular atrophy, a rare
neurodegenerative disease of motor neurons (Kolb & Kissel, 2015). In
this case, the antisense oligonucleotide, which is referred to as
nusinersen, is not acting to repress its target mRNA but to prevent
the binding of a splicing factor, thereby promoting alternative splicing
(Chiriboga et al., 2016). More conventional antisense oligonucleotides
that repress gene expression have not yet progressed so far through
the drug development pipeline for use in neurodegenerative diseases
but show promise. Most notably, these molecules have been shown
to decrease mutant gene expression and correspondingly improve the
clinical symptoms in preclinical models with a range of different poly-
glutamine repeat disorders. These include Huntington's disease, spinal
and bulbar muscular atrophy and a number of types of spinocerebellar
ataxia (Silva et al., 2020). Treatments have only reached the clinical
trial stage for Huntington's disease, but results have been impressive.
In particular, ISIS3139 (also known as RO7234292), an antisense oli-
gonucleotide also produced by Ionic Pharmaceuticals but this time
working with Hoffman-La Roche, was found to produce no serious
adverse effects while also lowering expression of mutant huntingtin
in the CSF in a combined Phase 1 and 2 clinical trial (NCT02519036;
clinicaltrials.gov) (Tabrizi et al., 2019). ISIS3139 has since progressed
to a Phase 3 trial (NCT03761849; http://clinicaltrials.gov), with results
expected in late 2022.
It is also worth observing that other antisense oligonucleotides are
under investigation for use in Huntington's disease, which, unlike
ISIS3139, specifically target mRNA produced by the disease-causing
allele and not the wild type (Silva et al., 2020). This is potentially signifi-
cant, because this strategy should in principle avoid reducing all
huntingtin expression, thereby protecting the essential functions of this
protein. Theoretically, PD patients with LRRK2 mutations (although not
sporadic PD patients) could be treated in a similar way. However, the
ability to select between mutant and wild type that differ only by a sin-
gle base change is going to be considerably more challenging than
mutations like the expanded CAG repeats causing Huntington's disease.
9 | ALLOSTERIC INHIBITORS OF LRRK2
KINASE ACTIVITY
Allosteric kinase inhibitors can be defined as compounds that inhibit
the enzymatic activity of a kinase by binding the kinase outside its
ATP-binding site and thus reducing kinase activity in an ATP
non-competitive manner (Lu et al., 2020). In principle, the GTPase
inhibitors described above, which bind the LRRK2 Roc domain and
indirectly reduce LRRK2 kinase activity, meet this definition, but we
have chosen to classify them separately, because kinase inhibition is
not their primary objective. In practice, allosteric inhibitors are more
likely to bind the kinase domain. There are advantages and disadvan-
tages with any therapeutic strategy, but allosteric compounds have
the potential to increase selectivity, by targeting regions that are less
conserved than the ATP-binding pocket, although designing such mol-
ecules is more challenging.
Recently, Schaffner et al. (2019) used a high-throughput screen of
Food and Drug Administration (FDA)-approved compounds to identify
a physiological form of vitamin B12 (50-deoxyadenosylcobalamin or
AdoCbl) as a non-ATP-competitive, ‘mixed-type’ allosteric inhibitor of
LRRK2 kinase activity. Because vitamin B12 levels are inversely corre-
lated with PD progression (Christine et al., 2018), these observations
suggest an intriguing, if speculative, hypothesis that endogenous vita-
min B12 levels may be affecting PD progression via modulation of
LRRK2 and that AdoCbl may be a bona fide endogenous inhibitor
of LRRK2 activity. In any case, with a reported IC50 of 1 μM in vitro,
AdoCbl is considerably less potent than conventional LRRK2 inhibi-
tors, although the authors suggest that AdoCbl is likely to be highly
selective for LRRK2 as this molecule is structurally dissimilar to any
other known kinase inhibitor. This last point clearly needs to be tested
empirically. In any case, this molecule was able inhibit LRRK2 kinase
activity and neurotoxicity in both in vitro and in vivo models carrying
pathogenic LRRK2 variants (Schaffner et al., 2019). The exact location
within LRRK2 to which AdoCbl binds was not identified but based on
enzymological data can be assumed to be distinct site(s) within the
LRRK2 kinase domain but outside the ATP-binding pocket.
The authors also report that AdoCbl disrupts LRRK2 dimerisation and
promotes the proteolytic degradation of this protein. How these
observations fit together mechanistically is not yet known, but
because LRRK2 dimers have greater kinase activity than LRRK2
monomers, it is tempting to speculate that AdoCbl may be inhibiting
LRRK2 kinase by preferentially binding to dimeric LRRK2 and inducing
monomerisation. This story is clearly at its infancy and therapeutic
potential of AdoCbl is unclear, but its identification as a new allosteric
inhibitor of LRRK2 may at least open the door to the discovery of
other similar molecules.
One strategy for the development of allosteric kinase inhibitors
of LRRK2 that may be slightly less useful is the development of ‘Type
II’ kinase inhibitors that target the DFGψ motif (sometimes abbrevi-
ated to DFG) of the kinase domain activation loop (Lu et al., 2020;
Schmidt et al., 2019). (Type II allosteric inhibitors in general bind to
kinase domain activation loops; DFGψ is a conserved sequence of
amino acids with the activation loop, where D, F and G are aspartic
acid, phenylalanine and glycine and ψ represents a hydrophobic
residue.) Importantly, Type II kinase inhibitors are only able to bind
kinase domain activation loops that are in an inactive ‘DFG-out’ con-
formation. In doing so, these compounds prevent the conformational
change to an active ‘DFG-in’ conformation that is required to allow
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access of ATP to the adjacent ATP-binding pocket (Schmidt
et al., 2019). As such, Type II kinase inhibitors block kinase activity by
gating access to ATP, rather than by competing with ATP. The limita-
tion of developing Type II kinase inhibitors that target the DFGψ
motif for LRRK2 is that this is the location of the amino acid substitu-
tions encoded by two pathogenic mutations, G2019S and I2020T. Sig-
nificantly, both G2019S and I2020T stabilise the LRRK2 activation
loop in the active DFG-in conformation (Liu et al., 2013; Ray
et al., 2014). Given this, Type II kinase inhibitors that target the DFGψ
motif of LRRK2 can be expected to be less effective against these
pathogenic variants than against wild-type LRRK2.
This expectation is supported by experimental data. To date, sev-
eral Type II inhibitors have been reported, including four compounds
identified by Liu et al. using molecular docking of previously described
Type II allosteric inhibitors of other kinases to a structural model of
the LRRK2 kinase domain (Liu et al., 2013; Ray & Liu, 2012). Two
of these inhibitors target the activation loop hinge region, rather than
the DFGψ motif, and these compounds displayed little difference in
potency when tested against wild-type LRRK2 and the G2019S and
I2020T variants (Ray & Liu, 2012). By contrast, the two DFGψ motif
inhibitors showed clear preferences for wild-type LRRK2, including
the most potent compound, ponatinib (O'Hare et al., 2009), which has
an in vitro IC50 for wild-type LRRK2 of 31 nM but only 200 and
600 nM for G2019S and I2020T, respectively (Ray & Liu, 2012).
Taken together, these observations suggest that Type II kinase inhibi-
tors that target the DFGψ motif will not be suitable for patients with
G2019S or I2020T LRRK2 mutations, although there is no a priori rea-
son why they may not be a valid therapeutic strategy for patients with
mutations outside the LRRK2 kinase domain or for idiopathic
PD. There is also no reason to doubt the potential of Type II kinase
inhibitors that target other parts of the activation loop. In addition to
the hinge region, Ray and Liu (2012) observed that a series of cysteine
residues located near the ATP-binding site might be a fruitful site for
developing covalent LRRK2 inhibitors.
10 | EVIDENCE OF NEUROPROTECTION
PROVIDED BY LRRK2 INHIBITORS OR LRRK2
ANTISENSE OLIGONUCLEOTIDES IN PD-
RELATED ANIMAL MODELS
Preclinical data—in particular, more physiologically relevant studies
performed in animal models—may provide some pointers towards the
results we might reasonably expect in patients. In this section, there-
fore, we briefly summarise experiments assessing the ability of LRRK2
kinase inhibitors and antisense oligonucleotides to promote cell sur-
vival in PD-relevant animal models.
Because LRRK2 transgenic animals do not have a robust neuro-
logical phenotype (Daniel & Moore, 2015; Seegobin et al., 2020),
in vivo investigations into neuroprotection offered by LRRK2 kinase
inhibitors have tended to use viral expression systems to transduce
animal brains with high levels of a pathogenic protein. In studies using
overexpression of the pathogenic G2019S LRRK2 variant, it seems
fairly clear that LRRK2 kinase inhibitors can effectively reduce the
resulting neurodegeneration in both mice (Lee et al., 2010) and rats
(Daher et al., 2015; Nguyen et al., 2020). These data are supported by
observations of an equivalent effect of introducing an artificial kinase
inactivating mutation into the overexpressed LRRK2 protein (Lee
et al., 2010; Nguyen et al., 2020; Tsika et al., 2015). Of note, muta-
tions that perturb LRRK2 GTPase function, by either blocking binding
to GTP or elevating the rate of GTP hydrolysis, cause a similar reduc-
tion in neurodegeneration, thus supporting the use of LRRK2 GTPase
inhibitors as an alternative strategy (Nguyen et al., 2020).
The above studies clearly demonstrate that LRRK2 kinase inhibi-
tion can be neuroprotective in vivo. However, there remains a ques-
tion as to how accurately the neurodegeneration caused by viral
overexpression of a pathogenic LRRK2 variant represents the normal
dopaminergic cell death in PD, where LRRK2 is not overexpressed.
So, what about other models of neurodegeneration? An alternative
experimental system is viral transduction of α-synuclein. Unfortu-
nately, results using these technologies are mixed. In the first study,
Daher et al. (2015) found that PF-06447475 reduced α-synuclein-
induced neurodegeneration in rats. By contrast, Andersen et al. (2018)
were unable to show neuroprotection or rescue of motor symptoms
using PFE-360, although they did report a reversal of an aberrant sub-
thalamic firing pattern that the authors describe as resembling alter-
ations seen in PD. However, in a follow-up report describing the
effects of longer term PFE-360 treatment, the same group found no
improvement in subthalamic nucleus firing, although a mild improve-
ment in motor function was observed (Andersen et al., 2019). Taking
their observations together, the authors conclude that their findings
‘do not strongly support LRRK2 inhibition for the treatment of PD’
(Andersen et al., 2019).
There are many potential reasons for the disagreement, such as
the different viral systems used, the degree of α-synuclein expression
achieved and the treatment times used. Although structurally very
similar (Figure 2), the LRRK2 inhibitors used could also be a factor. It
is also worth observing that even if the results were in complete
agreement, they would still need to be treated with caution, because
the rate at which α-synuclein accumulates in the brains of PD patients
cannot be anything like as fast as that achieved by viral transduction.
With this in mind, recent observations made using the pesticide
rotenone to induce dopaminergic neurodegeneration in mice may be
insightful (Rocha et al., 2020). This study measured both rotenone-
induced dopaminergic cell death and the preceding changes to
endolysosomal and autophagic systems that mirror defects seen in
the surviving neurons from patients with idiopathic PD (Rocha
et al., 2020). Remarkably, the Type I LRRK2 kinase inhibitor PFE-360
reduced the effects of rotenone on all these measures. It must be
stressed that these data are only directly transferable to humans who
develop PD following acute rotenone exposure, but these results are
nonetheless encouraging. Chronic exposure to pesticides including
rotenone is an established environmental cause of increased PD risk
and the endolysosomal and autophagic defects that were rescued are
consistent with idiopathic PD. As such, these data point to LRRK2
inhibitors having use in idiopathic PD and LRRK2 PD.
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Despite the widespread use of the neurotoxins
6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) to induce dopaminergic damage in rodent
PD models (Schober, 2004), we are aware of only one report of an
attempt to rescue the phenotype of animals treated with these com-
pounds using LRRK2 inhibition. This study used a low dose of MPTP
that was not toxic in wild-type animals but induced significant impair-
ments in transgenic mice that overexpress either wild-type LRRK2 or
G2019S-LRRK2, with a greater effect seen in the G2019S animals
(Arbez et al., 2020). Remarkably, treatment with LRRK2-IN-1 dramati-
cally reduced dopaminergic cell death and also rescued motor deficits
to a similar extent to L-DOPA (Arbez et al., 2020). There are clearly
some caveats with these data, not least the choice of LRRK2
inhibitor—more selective compounds are available—but these data are
nonetheless encouraging. Perhaps most informative is the fact that an
ordinarily subtoxic dose of MPTP was used, which would have caused
less dopaminergic damage than standard doses. Perhaps consistent
with this, the rotenone study mentioned above used a dosing regimen
optimised to cause the least amount of neurodegeneration required to
guarantee a reproducible motor deficit (Cannon et al., 2009). As such,
the studies of Rocha et al. and Arbez et al. most likely point to a situa-
tion where LRRK2 inhibitors may have great potential to maintain
motor function in PD patients, but only if administered while there are
sufficient dopaminergic neurons remaining.
Research into the therapeutic potential of LRRK2 antisense oligo-
nucleotides in preclinical models is also thin on the ground, although
the use of LRRK2 antisense oligonucleotides is to some extent
informed by the preclinical work using LRRK2 inhibitors described
above (and vice versa). The first study using LRRK2 antisense oligonu-
cleotides is that of Zhao et al. (2017), who investigated the effect of
intracerebral ventricular injection of Lrrk2 antisense oligonucleotides
in mice injected with synthetic α-synuclein fibrils. Somewhat surpris-
ingly, given that the two different antisense oligonucleotides used
only achieved a 50% reduction in Lrrk2 expression, both oligonucle-
otides markedly reduced α-synuclein aggregation and dopaminergic
cell death and almost entirely rescued motor defects (Zhao
et al., 2017). In the absence of independent replication, these observa-
tions must be treated with caution, but the idea that a modest knock-
down of LRRK2 expression is sufficient to elicit a significant biological
effect in the mouse brain is supported by the only other paper using
antisense oligonucleotides targeting LRRK2 in animal models. In this
report (Korecka et al., 2020), Korecka et al. (2019) used an antisense
oligonucleotide that they have previously shown to perturb the nor-
mal splicing of human LRRK2 mRNA by causing exon 41 to be skipped
causing no functional LRRK2 protein produced. When injected into
the cerebral ventricles of transgenic mice expressing human wild-type
or G2019S LRRK2, this antisense oligonucleotide elicited significant
decreases in phosphorylation of the LRRK2 substrate Rab10 and also
affected autophagic flux, despite causing exon 41 to be skipped in no
more than 30% of transcripts (Korecka et al., 2020).
Taken together, these studies provide evidence that both strate-
gies may prevent neurodegeneration and thus delay or halt the pro-
gression of PD. Furthermore, because modest effects on LRRK2
expression appear sufficient to elicit promising biological effects, the
data suggest that LRRK2 antisense oligonucleotides may be the more
effective strategy. In principle, this may suggest the existence of addi-
tional pathological mechanisms that are independent of LRRK2 kinase
activity. However, the lack of publications and issues with reproduc-
ibility make these predictions extremely speculative. Perhaps more
convincing is the suggestion that the degree of neurodegeneration
present at time of treatment will be a decisive factor in determining
whether inhibiting or knocking down LRRK2 can be effective. Where
sufficient dopaminergic neurons remain, these strategies may main-
tain motor function; but if the disease is too far advanced, targeting
LRRK2 may be to no avail.
11 | FINAL POINTS OF DISCUSSION
There are clearly a wide range of therapeutic strategies aiming to treat
both LRRK2 and idiopathic PD by reducing the function of this enig-
matic protein. These include both ATP-competitive and non-ATP-
competitive kinase inhibitors, pharmacological inhibitors of LRRK2
GTPase activity and knockdown of LRRK2 mRNA. The kinase inhibitor
DNL151 and the antisense RNA molecule BIIB094 are currently in
clinical trials with further results eagerly awaited. There is therefore
optimism within the field, as well as a plethora of fallback options
should DNL151 and BIIB094 fail.
Nonetheless, there are other aspects of LRRK2 biology that may
in future become viable therapeutic targets. As mentioned, LRRK2
dimers are believed to have greater kinase activity that LRRK2 mono-
mers, and the cycling of LRRK2 between these states is has been
suggested to play a key role in the normal regulation of this protein
(Berwick et al., 2019). Indeed, work performed in zebrafish models
indicates that the deletion of the C-terminal WD40 domain is suffi-
cient to prevent dimerisation, thereby reducing autophosphorylation
and reducing the neurotoxicity of LRRK2 (Jorgensen et al., 2009).
Thus, disruption of LRRK2 dimerisation can be expected to, in turn,
impair LRRK2 kinase activity, creating a mechanism that could be
harnessed for the development of selective inhibitors of LRRK2
kinase. Such approaches have already been used successfully to iden-
tify compounds that prevent dimerisation of other proteins, for exam-
ple, ST2825, a heptapeptide that blocks dimerisation of myeloid
differentiation primary response 88 (MyD88) (Loiarro et al., 2007).
However, this may be a trickier task for LRRK2, because LRRK2
dimerisation appears to have several intramolecular interactions
involved, with the WD40 and COR domains implicated in particular
(Greggio et al., 2008; Guaitoli et al., 2016; Jorgensen et al., 2009). As
such, efficient disruption of LRRK2 dimers may require a cocktail of
molecules, each targeting a different protein interaction interface.
On a similar note, in addition to roles as a kinase and GTPase,
LRRK2 has long been suggested to have a function as a scaffold pro-
tein, interacting with numerous other proteins to form dynamic signal-
ling complexes at specific cellular localisations (Berwick et al., 2019;
Lewis & Manzoni, 2012). As such, disruption of protein–protein inter-
actions required for the pathogenic effects of LRRK2 may be fertile
12 AZEGGAGH AND BERWICK
ground for drug discovery. Nonetheless, although many hundreds of
LRRK2 interaction partners have been reported, when the expression
levels of these proteins have been modulated in cellular models, very
few appear to exert a robust influence on measures relevant to patho-
genicity of PD-causing LRRK2 variants. An important exception, how-
ever, may be 14-3-3 proteins. 14-3-3 proteins bind LRRK2 in a
manner dependent on the phosphorylation of LRRK2. Phosphoryla-
tion sites to which 14-3-3 proteins associate include Ser910 and
Ser935, in the LRR domain (Nichols et al., 2010), Ser1444 in the Roc
domain (Muda et al., 2014) and Thr2524 at the very C-terminus
(Manschwetus et al., 2020). Although the interplay between these
14-3-3 binding events is complex and not yet fully understood, the
functional consequences of LRRK2 interacting with these proteins are
clear. Most notably, binding of 14-3-3 proteins to LRR domain resi-
dues stabilises LRRK2 in a monomeric and cytoplasmic form that can
be assumed to have decreased kinase activity (depicted in Figure 3).
Consistently, pathogenic LRRK2 mutations have been reported to dis-
rupt LRRK2–14-3-3 interactions (Lavalley et al., 2016; Nichols
et al., 2010). Based on these and other observations, Soliman
et al. (2020) have speculated that small molecule stabilisers of 14-3-3
protein–protein interactions, some of which have recently been
described in the literature (Ballone et al., 2018), could be used to pro-
duce molecules that stabilise LRRK2-14-3-3 complexes. We await the
next instalment of this story.
Finally, it is important to mention the impact two very recent
breakthroughs in LRRK2 structural biology that have already provided
data relevant to LRRK2 inhibitor development. In the first work,
Watanabe et al. (2020) used a combination of cryo-electron tomogra-
phy and integrative modelling to produce a 14-Å resolution in situ
model for the entire LRRK2 protein bound to microtubules
(PDB:6XR4). This model recapitulated the filamentous LRRK2 pheno-
type observed by others, where LRRK2 filament formation is
enhanced by both most LRRK2 pathogenic mutants and conventional
LRRK2 kinase inhibitors (Blanca Ramirez et al., 2017; Schmidt
et al., 2019), and found that LRRK2 filaments form via homotypic
interactions between COR and WD40 domains (Watanabe
et al., 2020). Fascinatingly, Deniston et al. (2020) integrated the 6XR4
structure with their own high-resolution (3.5 Å) cryo-electron micros-
copy structure of amino acids 1327–2527 of LRRK2, containing Roc,
COR, kinase and WD40 domains, to reveal further insights. Most
notably, this group confirmed the prediction made by Watanabe et al.
that LRRK2 would be more likely to form filaments when in a closed
kinase confirmation. This provides a rationale for why conventional
LRRK2 kinase inhibitors (i.e. ATP-competitive or Type I), which lock
LRRK2 in a closed kinase confirmation, promote filament formation. In
support of this, the Type II kinase inhibitors ponatinib (O'Hare
et al., 2009) and GZD-824 (Ren et al., 2013), which would be
expected to lock LRRK2 in an open kinase confirmation, were found
to prevent filament formation (Deniston et al., 2020). Interestingly,
this latter observation mirrors those made for the LRRK2 GTPase
inhibitors, compounds 68 and 60 (Blanca Ramirez et al., 2017).
In conclusion, therefore, with so many routes to achieving LRRK2
inhibition being taken, the prospects for developing new PD
medications based around targeting LRRK2 are good. Where lead
molecules and different strategies fall by the wayside, there are plenty
of alternatives to take over. Nonetheless, with two molecules in clini-
cal trials, the extent to which these treatments bring clinical benefits
will undoubtedly be the hot topic over the next few years.
11.1 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked
to corresponding entries in the IUPHAR/BPS Guide to
PHARMACOLOGY http://www.guidetopharmacology.org and are
permanently archived in the Concise Guide to PHARMACOLOGY
2019/20 (Alexander et al., 2019).
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